NCT01470690View on ClinicalTrials.gov

Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

January 31, 2012

Conditions
HCV InfectionsGastric Acid-related Disorders
Interventions
DRUG

boceprevir

Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5

DRUG

Omeprazole

Omeprazole 40 mg QD for 5 consecutive days

Trial Locations (1)

Unknown

Crcn, Runmc, Nijmegen

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Radboud University Medical Center

OTHER

NCT01470690 - Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO) | Biotech Hunter | Biotech Hunter